Payment overview · 2025
General Payments
$934.15
34 reported records · 19 companies
Healthcare provider profile · identity verified
Adrian L Burrowes, MD
Allopathic & Osteopathic Physicians|Family Medicine · CASSELBERRY, FL · NPI 1700822657
Verified facts
What the public records show
CMS Open Payments records show Adrian L Burrowes, MD received $934.15 in general payments during 2025 across 34 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $171.49 | 18.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $149.03 | 15.9% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $148.68 | 15.9% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $66.87 | 7.2% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $54.97 | 5.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.73 | 4.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $37.46 | 4.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.89 | 3.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.51 | 3.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.85 | 3.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.44 | 2.7% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $21.46 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.30 | 2.1% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $19.04 | 2.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.43 | 2.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $16.56 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.39 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.29 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.76 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $917.59 | 33 |
| Education | $16.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $208.95 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $148.68 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $136.19 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $66.87 | 4 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $54.97 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.73 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.85 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $12.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 496 | 99 |
| Eliquis | Apixaban | 437 | 61 |
| Gabapentin | Gabapentin | 404 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 82 |
| Losartan Potassium | Losartan Potassium | 303 | 70 |
| Lisinopril | Lisinopril | 240 | 51 |
| Metformin Hcl | Metformin Hcl | 210 | 41 |
| Furosemide | Furosemide | 206 | 54 |
| Potassium Chloride | Potassium Chloride | 206 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 36 |
| Trazodone Hcl | Trazodone Hcl | 196 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 48 |
| Alprazolam | Alprazolam | 166 | 54 |
| Sertraline Hcl | Sertraline Hcl | 165 | 32 |
| Carvedilol | Carvedilol | 161 | 36 |
| Tramadol Hcl | Tramadol Hcl | 160 | 39 |
| Donepezil Hcl | Donepezil Hcl | 159 | 32 |
| Simvastatin | Simvastatin | 144 | 38 |
| Famotidine | Famotidine | 124 | 34 |
| Montelukast Sodium | Montelukast Sodium | 122 | 28 |
| Xarelto | Rivaroxaban | 116 | 14 |
| Buspirone Hcl | Buspirone Hcl | 112 | 23 |
| Levetiracetam | Levetiracetam | 107 | 17 |
| Omeprazole | Omeprazole | 100 | 29 |
| Allopurinol | Allopurinol | 94 | 19 |
| Meloxicam | Meloxicam | 93 | 26 |
| Spironolactone | Spironolactone | 92 | 18 |
| Clonazepam | Clonazepam | 91 | 13 |
| Ezetimibe | Ezetimibe | 91 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 31 |
| Baclofen | Baclofen | 87 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 84 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 22 |
| Mirtazapine | Mirtazapine | 81 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 17 |
| Memantine Hcl | Memantine Hcl | 68 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 15 |
| Bumetanide | Bumetanide | 62 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 17 |
| Myrbetriq | Mirabegron | 61 | 14 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | suppressed |
| Prednisone | Prednisone | 52 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 25 |
| Pregabalin | Pregabalin | 50 | 12 |
| Risperidone | Risperidone | 50 | suppressed |
| Methocarbamol | Methocarbamol | 49 | 14 |
| Midodrine Hcl | Midodrine Hcl | 48 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 46 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Atenolol | Atenolol | 45 | 12 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Finasteride | Finasteride | 45 | 11 |
| Ibuprofen | Ibuprofen | 45 | suppressed |
| Torsemide | Torsemide | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Latanoprost | Latanoprost | 42 | 11 |
| Mounjaro | Tirzepatide | 41 | 13 |
| Valsartan | Valsartan | 41 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 37 | 11 |
| Lorazepam | Lorazepam | 36 | 15 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 11 |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | 14 |
| Azithromycin | Azithromycin | 31 | 26 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 25 |
| Eszopiclone | Eszopiclone | 30 | 13 |
| Novolog Flexpen | Insulin Aspart | 30 | 11 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 11 |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Ozempic | Semaglutide | 20 | suppressed |
| Procrit | Epoetin Alfa | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clozapine | Clozapine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Leflunomide | Leflunomide | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Clonidine | Clonidine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $934.15 · 34 records | Otsuka America Pharmaceutical, Inc. | Arikayce, Auvelity, Brinsupri, COLLAGENASE SANTYL, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, INGREZZA, INJECTAFER, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Leqembi, MOUNJARO, NUPLAZID, Ozempic, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error